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This study was aimed to investigate the disposition and pharmacokinetics of the total saponins of 
dioscorea (TSD) in rats. Male Sprague-Dawley rats were orally administrated with 3H labeled TSD at a 
single dose ratio of 80 mg TSD per 1 kg rat. Blood samples and feces were collected at different time 
points to measure the level of TSD activity. At the final time point, determination of the disposition of 
TSD in lung, kidney, heart, liver, adrenal, and small intestine were performed. From the blood samples’ 
emission of radioactivity, pharmacokinetic parameters were derived as T1/2 = 33.33 ± 4.48 h, Tmax = 6.5 ± 
0.71 h, AUC = 119400 ± 421097.67, and Cmax = 2643.33 ± 192.26 dpm/ml. There was 51.609% of 3H labeled 
substance excreted in 24 h. These results suggested that blood concentration of 3H-TSD was extremely 
low and the majority of TSD was excreted in the feces. The TSD was extensively distributed to multi-
tissues. The radioactivity level was measured to be the highest in the liver, adrenal gland, and wall of 
the gastrointestinal tract. The radioactivity of TSD was still being detected in blood after 96 h. This 
showed TSD was excreted in vivo very slowly.  
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INTRODUCTION 
 
In China, the total saponins of dioscorea (TSD) had long 
been used as major components in herbal medicines for 
treatments. Ingredients of TSD include dioscin, pseudo-
protodiscin, protodioscin and methyl protodioscin (Figure 
1), which were extracted from Dioscorea nipponica 
Makino. TSD is commonly used to treat diverse diseases 
is common in China as there are a number of bioactive 
compounds with pharmacologic effects in TSD; such as 
anti-cancer, immunomodulation, anti-diabetics and 
ameliorating myocardial ischemia (Chiang et al.,  1992; 
Mi et al., 2002; Yoshikawa et al., 2007). TSD are also the 
main ingredient in several Chinese medicine like 
Di’aoxinxue-kang capsule and Weiao Xin capsule, which  
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are used to treat coronary heart disease in China for 
many years (Liu et al., 2004). 
Several studies had previously investigated the meta-
bolism and pharmacokinetics of some pure steroidal 
saponin in TSD, such as dioscin (Li et al., 2005; Li et al., 
2005) and methyl protodioscin (Cao et al., 2007; He et al., 
2006). The total saponins have been analyzed and 
reported as well (Lin et al., 2007). The HPLC experiments 
were performed by means of a reversed-phase C18 
column and a binary mobile phase system consisted of 
water and acetonitrile under gradient elution conditions in 
vitro. 
In addition, due to the amount of TSD being absorbed 
in human body was few (Lin, 2007), the measurements of 
pharmacokinetics are difficult to be performed. Thus, it is 
necessary to establish high sensitive analytical methods 
for determination of the pharmacokinetics of TSD in 
circulation. Recently we developed a method to measure 
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Figure 1. Structures of dioscin, pseodoprotodiscin, protodioscin and methyl protodioscin. 
 
 
 
TSD in rat plasma with liquid chromatography tandem 
multi-stage mass spectrometry in vitro (Lin et al., 2007). 
However, no one has ever reported that the signal inten-
sities of TSD obtained in positive in infinitesimal in vivo. 
There are some advantages about radioactive labeled, 
such as sensitivity which can have infinitesimal solution.   
In this study, we developed a specific radioactive assay 
and characterized the pharmacokinetic parameters of 
TSD in rats was characterized after a single oral 
administration dose. To understand the characterization 
of the disposition and pharmacokinetics of the 3H –TSD, 
this study utilized SD rats by orally administering the rats 
with a single dose of 3H –TSD. Here, we report the 
pharmacokinetic activities in blood, tissue distribution and 
excretion studies of the herb in rats. 
 
 
MATERIALS AND METHODS 
 
Drug preparation 
 
TSD powder (the content of total saponins was 90.2% by HPLC, 
product No.19990618) was obtained from Pharmaceutical Corp of 
Di’ao group (Chengdu, China). 3H labeled TSD was placed with 
compared items under microwave stimulation exchange method (3H 
labeled twice, pure by silicon) by China Nuclear Science Academy 
(Beijing). The purity of radioactive substance was 63.3%, and the 
3H concentration was 1 mci/800 mg (according to pre-tests, the 
minimal and optimal concentration were selected). The radioactive 
substance was kept at -20°C before use. Methylene dichloride, 
dimethylbenzene, perchloric acid, hydrogen peroxide (analytically 
pure) and PPO scintillator liquid were used as reagents in the 
experiment. The rats were fed with 3H labeled TSD at a single dose 
of 80 mg/kg body weight of the rat (radioactive concentration 250 
µci/ml). 
 
 
Method validation 
 
A standard curve of 3H–TSD was obtained by adding 3H–TSD to 0.2 
ml of blood in a series of dilution: 0, 1250, 2500, 5000, 10000, 
20000, 40000, and 80000 dpm. The equation shows (in results 
section) the relationship between radioactive dosage and dpm. The 
relative standard deviation (R.S.D.) was used to report the precision. 
The lower limit of quantization (LLQ) was assessed by analyzing 8 
samples of blood.  
Animals 
 
The animal study has approved by ethic committee of Sun Yat-Sen 
University. Male Sprague-Dawley rats, weighing 230±15 g were 
purchased from the Animal Center of Sun Yat-Sen University 
(Guangzhou, China). Rats were housed under constant tempera-
ture and humidity using sterile bedding control room with a 12-hour 
in dark to12-hour in light cycle. They were given free food and 
water. The rats were fasted overnight before administration with a 
single dose of 3H-TSD. 
 
 
Blood sample collection (pharmacokinetic) 
 
The rats had been under anesthetized prior to blood taking. The 
blood samples in amount of 150 µl blood with anticoagulant were 
collected from each rat by the puncture of the retro-orbital sinus. 
This was performed at 0 (predose), 0.5, 1, 2, 4, 6, 8.5, 12, 24, 36, 
48, 72, 96 and 120 h after oral administration of 3H-TSD. 
 
 
Tissue distribution study 
 
At the time point 120 h, the rats were then sacrificed by 
decapitation. The lung, kidney, heart, liver, adrenal gland, and small 
intestine were immediately removed. The tissue amples of (100 mg) 
were minced and homogenized in methanol (0.5 ml). These tissues 
were collected and stored at −80°C for further analysis. 
 
 
Excretion study 
 
The animals were housed in metabolic cages and were given free 
food and water during the course of the experiment. Pooled urine 
from each rat was collected from 0, 0 - 2, 2 - 4, 4 - 6, 6 - 8.5, 8.5 - 
12, 12 - 24, 24 - 48, 48 - 96 h after administration, fecal samples 
(50 mg) were dried homogenized and stored at −20°C until analysis. 
The 3H-TSD in the urinary and fecal excretion of the rats was 
determined. 
 
 
Radioactive analysis 
 
For radioactive analysis, 0.3 ml perchloric acid and 0.2 ml H2O2 
(hydrogen peroxide) methylbenzene were put into the blood. The 
blood was then incubated at 80°C for 50 min. The resulted solution 
(200µl) was added to PPO scintillator liquid and measured with  the 
LCD reader Beckman Ls6500II (USA).  
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Figure 2. Mean whole blood radioactive concentration-time profiles 
of the TSD 3H labeled after oral administrations to rat (n = 6). 
 
 
 
Statistic analysis  
 
For statistic analysis, the software of WinNonlin (Pharsight 
Corporation, CA USA) was used. 
 
 
RESULTS 
 
Validation 
 
The equation below shows the relationship between 
radioactive dosage and dpm. A standard curve of the 3H-
TSD. A good linearity (r = 0.995, P < 0.05) was found in 
the regression analysis of the AUC0−t-dose plot. 
 
Y = 190.02X – 271.71   R = 0.9991  
 
 
Pharmacokinetic studies 
 
TSD in blood concentration for individual rats were 
analyzed by compartmental analysis using the WinNonlin 
(Pharsight Corporation, CA USA). Area under the curve 
(AUC0−t) was calculated using the linear-trapezoidal rule, 
with extrapolation to infinity (AUC0−∞) from the last 
detectable concentration. The absolute oral bioavailability 
(F) was determined as F = (AU Coral/AUCI.V.) × 100%, 
using mean AUC values for the oral dose. T-test with 
P < 0.05 was taken as significant. The concentration-time 
profiles of the administration was measured (Figure 2)   
and pharmacokinetic parameters are listed (Table 1). The 
results showed that the radioactivity and pharmaco-
kinetic parameters were low, due to the extremely low 
blood concentration after the oral dose of 80 mg 3H-TSD 
per kilogram of rats, the radioactivity and pharmaco-
kinetic parameters shown is low.  
 
 
Tissue distribution study  
 
As shown in Figure 3 the 3H-TSD in the  adrenal  glands,   
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Table 1. The drug pharmacokinetic parameters X ± SD, n = 6. 
 
PK parameters X ± SD 
Dose (µCi/kg) 1000 µci/Kg 
tmax  (h) 6.5 ± 0.71 
Cmax  (dmp/mL) 2643.33 ± 192.26 
Half time
  
(h) 33.33 ± 4.48 
AUC0-t  (h*dmp/mL) 119400.00 ± 21097.67 
AUC0-inf   (h*dmp/mL) 131701 ± 21837.25 
Volume (L/kg) 1.09*108 ± 4.02*107 
CL/F(L/h/kg)  20126667 ± 4333248.70 
 
Explanation: one time feeding (the dose is 80 mg/Kg), 14 point was 
be observed about 120 h collected parameter of pharmacokinetic. 
AUC: area under the concentration of blood and time; t1/2: half time 
dose of decline; Cmax: the biggest concentration of blood. 
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Figure 3. Dose of radioactive in tissues of body (X ± SD). 
Cumulative excretion of radioactivity in organ after single dosage of 
3H TSD labeled drug (the dose is 80 mg/Kg) to the SD rats. 
After120 h, radioactivity is still detected in organs and extensively 
distributed in many tissues and organs. 
 
 
 
small intestine, and liver were higher when compared 
with other organs at the 120th h. The highest level of TSD 
was found in adrenal glands and intestinal contents 
(Figure 3). The obtained data indicates that oral TSD 
could retained in the adrenal tract and intestinal tract for 
an extended period and absorbed TSD is widely 
distributed around the body.  
 
 
Excretion study 
 
The radioactivity of 3H-TSD was collected and was 
detected in feces at different time points. The cumulative 
radioactivity amount was 51.6% after 24 h administration 
(Table 2). There was no radioactivity found in urine within  
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Table 2. Excretion of radioactive substance (n = 6). 
 
Time interval (h) Excretion (%) Accumulative (%) 
0 - 2 0.00302 0.00302 
2 - 4 10.8539 10.8579 
4 - 6 9.11602 19.9653 
6 - 8.5 11.0407 31.0057 
8.5 -12 10.3551 41.3608 
12 - 24 10.2482 51.6090 
24 - 48 1.7656 53.3746 
48 - 96 1.6402 55.0158 
 
Cumulative excretion of radioactivity in feces after single dosage of 3H-
TSD (80 mg/Kg) to the SD rats; tests of radioactivity were conducted at 
different time intervals. 
 
 
 
24 h (Table 2).  
 
 
DISCUSSION 
 
The pharmacokinetics of oral TSD to rat is characterized 
by long tmax and t1/2. Drugs that undergo entero-hepatic 
recycling are often characterized by a long half-life and 
having multiple peaks in the concentration–time profile. In 
the present study, TSD was found to have a long half-life 
in rat which reveals that 3H-TSD absorption in vivo is very 
low in content, but quick in rate, and it reaches peaks 
within 4 to 6 h. After 96 h, traces of radioactivity can still 
be detected in blood. At various time points, however, the 
dpm proportion is only 2% of the total given amount. The 
result is similar to others in the literature (Ma et al., 2002; 
Li, 2005). 
The repeated tests within 100 h through the entero- 
hepatic recycling into the blood of TSD time curve show 
many peaks. These peaks distort the calculation of 
pharmacokinetic parameters and the results suggest that 
entero-hepatic recycling is important. 
3H-TSD is expeled slowly from rat. It can even be 
traced in liver, adrenal gland, and intestinal tract, but little 
in the heart. The long tmax is a special pharmacokinetic 
characteristic of 3H-TSD by oral administration, as even 
at the 120 h time point, the level of 3H-TSD remained 
high in the adrenal gland, intestinal, and liver contents. 
This may be an important factor resulting from the 
continuous absorption of the drug from the intestinal tract. 
Our results shows that 3H-TSD was mainly excreted in 
the feces up to 40 - 50% in 12 h, but it could not be found 
in urine.  
After 120 h the rat tissues were tested for radioactivity. 
Data reveals that the liver, kidney, and heart have traces 
of radioactivity. Liver, adrenal gland, and intestines have 
higher rates of absorption. It is very interesting that less 
absorption of TSD in the heart help treat heart diseases. 
It is possible that TSD acts upon the endocrine system to 
meditate the cardiovascular functions. Through in vitro 
study of the dissected heart organ, we  applied  TSD  and  
 
 
 
 
discover no improvement on cardiovascular functions 
after application of TSD. On the contrary, we detected 
toxic side effect which explains TSD in its original form 
has no direct pharmaceutical benefit. However, its 
metabolites can trigger bioactivity (Mitchell et al., 1979; 
Han, 1999).  
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